Universal Biosensors’ (UBI) underlying technology and expertise is in the development and manufacture of electrochemical cells used to measure markers in various sample types.
Starting with the blood glucose monitoring market, history showed with their ease of use, reliability and affordability, electrochemical based tests have proved to be commercially successful. However, despite their success, limitations in the way electrodes perform on blood samples have always meant that the results were never quite as accurate as test results from the laboratory.
These first generation electrochemical cells traditionally used electrodes positioned within the cell in a side-by-side or ‘co-planar’ layout to minimise electrical interference between the electrodes. This configuration limited the ability to correct for chemical interferences or test to test variations.
A significant breakthrough discovered and developed by Universal Biosensors’ scientists and engineers was the understanding that the interference between electrodes is predictable and can be described mathematically. Surprisingly, this previously discarded “electrical inference” yields additional information about the sample including information which can correct test to test variations that may be present in a specific sample type.
The novel opposing electrode configuration used in Universal Biosensors’ platform also removes the limitations which previously prohibited expansion of electrochemical cell technology to the testing of other substances. This opposing electrode technology forms the basis for extension into other POC devices as well as other point of use devices in alternative industries. This technology has the following advantages: